Nanoparticles for the treatment of liver fibrosis

Suchithra Poilil Surendran, Reju George Thomas, Myeong Ju Moon, Yong Yeon Jeong Department of Radiology, BioMolecular Theranostics (BiT) Lab, Chonnam National University Medical School, Chonnam National University Hwasun Hospital (CNUHH), South Korea Abstract: Chronic liver diseases repre...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Poilil Surendran S, George Thomas R, Moon MJ, Jeong YY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Fibrosis Inorganic Nanoparticles Liposomes Micelles. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/558918bce01243c98ed8b407583a9daa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:558918bce01243c98ed8b407583a9daa
record_format	dspace
spelling	oai:doaj.org-article:558918bce01243c98ed8b407583a9daa2021-12-02T02:28:14ZNanoparticles for the treatment of liver fibrosis1178-2013https://doaj.org/article/558918bce01243c98ed8b407583a9daa2017-09-01T00:00:00Zhttps://www.dovepress.com/nanoparticles-for-the-treatment-of-liver-fibrosis-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Suchithra Poilil Surendran, Reju George Thomas, Myeong Ju Moon, Yong Yeon Jeong Department of Radiology, BioMolecular Theranostics (BiT) Lab, Chonnam National University Medical School, Chonnam National University Hwasun Hospital (CNUHH), South Korea Abstract: Chronic liver diseases represent a global health problem due to their high prevalence worldwide and the limited available curative treatment options. They can result from various causes, both infectious and noninfectious diseases. The application of nanoparticle (NP) systems has emerged as a rapidly evolving area of interest for the safe delivery of various drugs and nucleic acids for chronic liver diseases. This review presents the pathogenesis, diagnosis and the emerging nanoparticulate systems used in the treatment of chronic liver diseases caused by liver fibrosis. Activated hepatic stellate cell (HSC) is considered to be the main mechanism for liver fibrosis. Ultrasonography and magnetic resonance imaging techniques are widely used noninvasive diagnostic methods for hepatic fibrosis. A variety of nanoparticulate systems are mainly focused on targeting HSC in the treatment of hepatic fibrosis. As early liver fibrosis is reversible by current NP therapy, it is being studied in preclinical as well as clinical trials. Among various nanoparticulate systems, inorganic NPs, liposomes and nanomicelles have been widely studied due to their distinct properties to deliver drugs as well as other therapeutic moieties. Liposomal NPs in clinical trials is considered to be a milestone in the treatment of hepatic fibrosis. Currently, NP therapy for liver fibrosis is updating fast, and hopefully, it can be the future remedy for liver fibrosis. Keywords: liver fibrosis, inorganic nanoparticles, liposomes, micellesPoilil Surendran SGeorge Thomas RMoon MJJeong YYDove Medical PressarticleFibrosisInorganic NanoparticlesLiposomesMicelles.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 6997-7006 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Fibrosis Inorganic Nanoparticles Liposomes Micelles. Medicine (General) R5-920
spellingShingle	Fibrosis Inorganic Nanoparticles Liposomes Micelles. Medicine (General) R5-920 Poilil Surendran S George Thomas R Moon MJ Jeong YY Nanoparticles for the treatment of liver fibrosis
description	Suchithra Poilil Surendran, Reju George Thomas, Myeong Ju Moon, Yong Yeon Jeong Department of Radiology, BioMolecular Theranostics (BiT) Lab, Chonnam National University Medical School, Chonnam National University Hwasun Hospital (CNUHH), South Korea Abstract: Chronic liver diseases represent a global health problem due to their high prevalence worldwide and the limited available curative treatment options. They can result from various causes, both infectious and noninfectious diseases. The application of nanoparticle (NP) systems has emerged as a rapidly evolving area of interest for the safe delivery of various drugs and nucleic acids for chronic liver diseases. This review presents the pathogenesis, diagnosis and the emerging nanoparticulate systems used in the treatment of chronic liver diseases caused by liver fibrosis. Activated hepatic stellate cell (HSC) is considered to be the main mechanism for liver fibrosis. Ultrasonography and magnetic resonance imaging techniques are widely used noninvasive diagnostic methods for hepatic fibrosis. A variety of nanoparticulate systems are mainly focused on targeting HSC in the treatment of hepatic fibrosis. As early liver fibrosis is reversible by current NP therapy, it is being studied in preclinical as well as clinical trials. Among various nanoparticulate systems, inorganic NPs, liposomes and nanomicelles have been widely studied due to their distinct properties to deliver drugs as well as other therapeutic moieties. Liposomal NPs in clinical trials is considered to be a milestone in the treatment of hepatic fibrosis. Currently, NP therapy for liver fibrosis is updating fast, and hopefully, it can be the future remedy for liver fibrosis. Keywords: liver fibrosis, inorganic nanoparticles, liposomes, micelles
format	article
author	Poilil Surendran S George Thomas R Moon MJ Jeong YY
author_facet	Poilil Surendran S George Thomas R Moon MJ Jeong YY
author_sort	Poilil Surendran S
title	Nanoparticles for the treatment of liver fibrosis
title_short	Nanoparticles for the treatment of liver fibrosis
title_full	Nanoparticles for the treatment of liver fibrosis
title_fullStr	Nanoparticles for the treatment of liver fibrosis
title_full_unstemmed	Nanoparticles for the treatment of liver fibrosis
title_sort	nanoparticles for the treatment of liver fibrosis
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/558918bce01243c98ed8b407583a9daa
work_keys_str_mv	AT poililsurendrans nanoparticlesforthetreatmentofliverfibrosis AT georgethomasr nanoparticlesforthetreatmentofliverfibrosis AT moonmj nanoparticlesforthetreatmentofliverfibrosis AT jeongyy nanoparticlesforthetreatmentofliverfibrosis
_version_	1718402467244277760

Nanoparticles for the treatment of liver fibrosis

Ejemplares similares